Competition intensifies over market for DNA-based prenatal tests

Prenatal DNA testing has been a fiercely contested market of late. Yet another competitor entered the fray last week when Natera, a startup based in San Carlos, California, announced the 1 March launch date of a commercial test that can detect chromosomal abnormalities in the developing fetus from just a drop of an expectant mother’s blood—and with a sensitivity on par of that of more invasive techniques such as amniocentesis and chorionic villus sampling, both of which carry an elevated risk of miscarriage.

Natera now joins three other California-based firms—Sequenom, Verinata Health (a division of sequencing giant Illumina) and Ariosa Diagnostics—in offering such products for women at high risk of having babies with Down’s syndrome or other chromosomal miscounts known as aneuploidies. With US health insurers, including Aetna and Wellpoint, saying they plan to cover the new tests, the market for DNA-based prenatal screening now provides “a billion dollar opportunity,” according to David Ferreiro, an analyst at Oppenheimer & Co. in Boston.

Between the four new tests, Verinata’s and Sequenom’s currently offer the widest range of screening options, with the ability to identify disorders associated with an extra X or Y sex chromosome, such as Klinefelter’s (XXY) and triple X syndrome. This flexibility is reflected in the cost: Sequenom’s MaterniT21 PLUS carries a list price of $2,762, almost twice as much as Natera’s Panorama, which can detect a missing X chromosome but not other kinds of sex chromosome irregularities.

The tests’ sensitivities vary depending on the chromosome, but all companies claim to be able to identify a fetus with Down’s syndrome, caused by three copies of chromosome 21, more than 99 times out of 100. Detecting extra copies of chromosome 13—a condition known as Patau’s syndrome—is more difficult, and Ariosa’s Harmony test does poorest here, with only 80% sensitivity. But it’s also the cheapest, with a sticker price of just $795 (see chart for the full comparison).

Noninvasive Prenatal Genetic Tests Compared{credit}Nature Medicine{/credit}

For now, the DNA-based tests are only thought to provide a screening tool for select populations, and are not considered definitively diagnostic by clinician groups such as the National Society of Genetic Counselors, who worry about the possibility of erroneous results, the lack of data in low-risk populations and the limited number of aneuploidies tested. Thus, most experts—and many of the companies themselves—still recommend that women whose DNA-based tests come back positive follow up with conventional tests such as amniocentesis. Although the additional testing will still mean invasive procedures for some pregnant women, and their attendant complications, “you are limiting those invasive tests to only the high risk groups,” says Joan Scott, a genetic counselor and executive director of the National Coalition for Health Professional Education in Genetics in Lutherville, Maryland.

Ultimately, “women and their providers [need to be] well informed about the benefits and limitations that are inherent in all these tests,” says Scott. “It’s not a cut and dried decision.”

A version of this story appears in the April 2013 issue of Nature Medicine.

Proposal to overhaul disease’s name could boost awareness and funding

{credit}Shutterstock{/credit}

There’s an idea in linguistics known as the Whorfian hypothesis. It proposes that language is inexorably linked with how we perceive and think about the world. The classic argument is this: an Inuit person, possessing different names for snow, has the ability to think about, and even see, subtle differences in snow that speakers of some other languages do not.

Could the same apply to biomedicine?

Last week, a panel convened by the US National Institutes of Health (NIH) released a series of recommendations about how best to study and diagnose a common hormonal disorder in women known as polycystic ovary syndrome (PCOS). At the top of their list: a call for a name change.

It might seem counterintuitive that a name could be critical to scientific investigation. After all, a disease such as PCOS, which affects one in ten women of reproductive age and is a major cause of infertility, is still just that—no more or less common, no more or less severe, regardless of the name. Still, the semantics of a particular moniker can have potential repercussions, from levels of research funding to how patients find the right doctor.

PCOS affects an estimated five million women in the US and encompasses a range of symptoms, including high levels of the male hormone androgen, insulin-resistance, an increased risk of type 2 diabetes, abnormal hair growth and growths on the ovaries. However, little is known about the underlying causal mechanisms of the disease. As a result, there are currently no cures, only treatments for symptoms. Combined with the fact that many women express only some of these symptoms, the diagnostic criteria for PCOS are still under debate.

A distraction and an impediment

Late last year, the NIH called for an independent panel—four experts not involved in PCOS research—to assess this issue. Over the course of the December 2012 workshop, the panelists soon came to a realization: “We believe the name ‘PCOS’ is a distraction and an impediment to progress.  It causes confusion and is a barrier to effective education of clinicians and communication with the public and research funders,” panel member Robert Rizza, executive dean for research at the Mayo Clinic in Rochester, Minnesota, said in a teleconference last week unveiling the committee’s findings.

After reviewing the current state of research and different diagnosing standards, Rizza and his colleagues concluded that the presence of “polycystic ovary”—which is actually a misnomer, as the numerous ‘cysts’ on the ovary are really immature eggs known as follicles—is not sufficient to diagnose PCOS. Some women with excess follicular growth show no signs of having the disease; others show some combination of symptoms but have no ovarian abnormalities.

In their report, the panelists agreed with the relatively-contentious ‘Rotterdam criteria‘, which require patients to have two out of three major symptoms—increased androgen levels, irregular periods, and “polycystic ovary”—for a diagnosis. Therefore, they wrote, “It is time to expeditiously assign a name that reflects the complex metabolic, hypothalamic, pituitary, ovarian and adrenal interactions that characterize the syndrome,” and not just focus on one particular symptom. But being outsiders to PCOS research, they declined to propose a new name.

“Our feeling was that this was the right time to rebrand,” panelist Timothy Johnson, chair of the department of obstetrics and gynecology at the University of Michigan Medical School in Ann Arbor, told Nature Medicine. “The new name would really make people think about the disease in a broader way, do research in a broader way and get a broader range of funding.”

Continue reading

Microarrays outperform karyotyping in prenatal diagnoses

Testing fetal DNA for fine-scale copy number variations can reveal more genetic defects than standard karyotyping methods that look for genetic abnormalities in developing fetuses on a whole-chromosome level, according to the largest clinical trial of its kind.

“These findings will undoubtedly cause many clinical and laboratory geneticists to consider whether chromosomal microarrays should be recommended as a first-tiered prenatal diagnostic test,” says Cynthia Morton, director of cytogenetics at the Brigham and Women’s Hospital in Boston, who was not involved in the trial.

Karyotypic staining analyzes the composition and structure of chromosomes to reveal abnormal changes in chromosome number and shape that are commonly implicated in disease. This technique is currently the gold standard for detecting prenatal genetic defects, but is far from perfect. Karyotyping routinely misses small genetic aberrations and the method only works on cultured cells. To overcome these limitations, researchers have recently turned to a method known as ‘array-comparative genomic hybridization’, which relies on a small chip embedded with millions of molecular probes that recognize particular genomic DNA regions and pinpoint genetic abnormalities too small to be detected by current methods. And as an added bonus, it works on any tissue, living or dead.

Such ‘chromosomal microarrays’ have historically only been used in small scale studies for prenatal diagnostics. But now, a team led by Ronald Wapner, director of Maternal Fetal Medicine at the Columbia University Medical Center (CUMC) in New York, has tested fetal DNA from more than 4,400 expectant mothers at 29 centers across the US using both standard karyotyping and chromosomal microarrays. Microarray analysis, the researchers found, detected chromosomal deletions or duplications in 6% of cases in a group that was flagged as structurally abnormal by ultrasound but scored normal by karyotyping and also revealed genetic abnormalities in about 2% cases missed by karyotyping in another group with advanced maternal age.

“The advantage of microarrays is their high resolution and sensitivity, which allows detection of events at the level of genes, as opposed to the level of chromosomes for karyotyping,” says Wapner, who published the results today in the New England Journal of Medicine (NEJM).

Also today in NEJM, a team led by Uma Reddy, an obstetrician-gynecologist at the US National Institute of Child Health and Human Development in Bethesda, Maryland, compared the ability of microarrays and karyotyping to diagnose the cause of more than 500 stillbirths. Because of the challenges associated with culturing tissue from a dead fetus, karyotyping failed to give results in 30% of cases, whereas microarrays, which don’t require live cells, yielded a genetic culprit in 87% of stillbirth cases. “With microarrays, you are more likely to obtain a result, which is important for families waiting for answers,” says Reddy.

Continue reading

‘The Vagina Catalogues’ show a microbiome in flux, sometimes daily

When the vaginal microbiome gets out of whack, it causes an uncomfortable, often chronic condition known as bacterial vaginosis, which is associated with pregnancy complications such as premature birth as well as a heightened risk of contracting sexually transmitted diseases. But finding ways to return the disrupted vaginal microbiome to its normal, healthy state has proven difficult because nobody knows what ‘normal’ really means.

As Nature Medicine reported in a July 2011 news feature, a team of scientists at the University of Maryland School of Medicine in Baltimore had found that there are many naturally occurring versions of the microbiome, in part because the bacteria present in a woman’s vagina may vary according to her ethnicity. In a paper published today in the journal Science Translational Medicine, the same team goes on to show that although ethnicity can predict the make up of a the vaginal microbiome over a lifetime, in individual women this bacterial community can change dramatically within a matter of days—often without causing any effects on health.

To characterize this microbial variability, the scientists recruited 32 healthy volunteers for a labor-intensive study. The women enrolled, half of whom were black and half of whom were white, self-sampled vaginal swabs twice a week for more than three months and sent them off to the lab of lead author Jacques Ravel and his collaborator, Larry Forney of the University of Idaho in Moscow. There, biologists sequenced the genomes of the bacteria present in the samples to determine the relative abundance of, for example, the common bacteria species Lactobaccilus or Anaerococcus. For each woman, a picture emerged of a unique and surprisingly mercurial bacterial community. “There has been an assumption that microbiomes are stable over time,” says Forney. “But we found that over the course of just a few days, the entire microbial community could change in a given woman.”

These findings could help biologists develop personalized treatments for bacterial vaginosis, yeast infections and other conditions in which the microbiome is disturbed. “Right now, the antibiotic and probiotic treatments that exist for these diseases work for some women but not for others, and that’s because we don’t understand the environment we’re trying to treat,” says Forney. The hope, he and his colleagues say, is that these findings will lead to new treatments tailored to specific groups of women.

To move toward that goal, they have already begun enrolling more than 160 women to take daily vaginal samples for a larger, more rigorous study of how the various ‘normal’ microbiomes they identified in today’s paper change when a healthy woman develops a vaginal infection. “We need to start rethinking the idea of personalized treatment for diseases of the vagina,” says Ravel.

To read ‘The Vagina Catalogues’ click here.

Artwork by Alyssa Grenning

Fluke’s testimony highlights broad uses of birth control, but pain applications go beyond ovarian cysts

The Affordable Care Act contraceptive coverage currently being debated in the US Congress could allow institutions that provide health insurance to opt-out of covering birth control pills for religious or moral reasons. Such policies have, in the past, raised difficulties for women prescribed the drugs for noncontraceptive uses, such as the treatment of pain from ovarian cysts. On 23 February, a law student at Georgetown University named Sandra Fluke testified before the US House Committee on Oversight and Government Reform that when insurance coverage doesn’t cover contraceptives, it can deny women such a friend of Fluke’s with polycystic ovarian syndrome access to birth control prescribed to treat the condition. And although such treatments do not cure the underlying causes of such conditions—oral contraceptives do not shrink ovarian cysts—there is accumulating evidence that they can be used as analgesics, allowing women to avoid invasive surgeries to remove abnormal tissue from the uterus or ovaries. The debate over limiting coverage by private insurance for contraceptives raises the question of whether denying access will cause real, physical pain to women in the US.

Prescription for pain from ovarian cysts is just one of many noncontraceptive uses of popular combination hormonal birth control pills such as Yaz, Orthocept and Ortho Novum, which prevent pregnancy by suppressing ovulation or blocking proliferation of the endometrial lining of the uterus, deterring implantation of an egg. “Birth control is also a widely prescribed treatment for pain from endometriosis and fibroid tumors in the uterus,” says Joyce King, a nurse at Emory University in Atlanta who studies the benefits of contraceptives.

Continue reading

VIDEO: Stem cell discovery puts women’s reproduction on fertile ground

Researchers have discovered a population of human ovarian stem cells with the potential of forming new eggs during a woman’s reproductive years. The findings, reported online today (26 February) in Nature Medicine, could lead to new therapies that help extend female fertility into late middle age and beyond.

“For women’s reproductive health these findings have so many ramifications,” says study author Jonathan Tilly, a reproductive biologist at the Massachusetts General Hospital and the Harvard Medical School in Boston. “If we can get to the stage of generating functional human eggs outside the body, it would essentially rewrite human assisted reproduction.”

HPV vaccination for boys called into question

Texas Governor Rick Perry has taken a lot of flak for mandating that adolescent girls in the Lone Star State should be vaccinated against the human pappilomavirus (HPV). But Perry’s policy might have a strong scientific grounding. According to a report published today in PLoS Medicine, blanket vaccinating young girls might be the most effective way of curbing the cancer-causing virus.

A team led by Johannes Bogaards, a biostatistician at the VU University Medical Centre in the Netherlands, devised a mathematical model of sexually transmitted infections to investigate whether vaccinating males only, females only or both sexes was the best way to reduce the prevalence of such diseases. The researchers found that single-sex vaccination was most effective, and that the sex vaccinated should be the one with the highest prevalence of the disease.

Since HPV is more common among girls than boys, “vaccinating additional females is more effective in blocking transmission and reducing the population prevalence of infection than it is to start vaccinating males,” Bogaards says.

That conclusion runs counter to recent policy recommendations made by the US Centers for Disease Control and Prevention (CDC). In October, the agency recommended that young boys should be vaccinated alongside their female schoolmates to help stem the transmission of the virus.

Despite the Dutch team’s analysis, however, Joseph Bocchini, chairman of the CDC advisory committee on HPV, stands by his agency’s recommendations. He notes that sociopolitical stigma and misinformation have led to low vaccination rates in the US that upset many of the assumptions of the Dutch model. As such, he explains, “the fewer women who are immunized the more we stand to gain from vaccinating boys.”

The mathematical model also assumes only heterosexual disease transmission, notes pediatrician Luis Barroso of Wake Forest University in North Carolina. The analysis “doesn’t take into account men having sex with men,” who would get “no protection at all from vaccinating women,” he says. That’s why, in addition to adolescent boys, the CDC’s October report recommended vaccination for men up to age 26 if they have sex with other men.

Such disagreements within the scientific community reflect the difficulty of creating an epidemiological model that can be widely applied. One thing epidemiologists, biostaticians and policymakers all agree on is that the HPV vaccine is safe, effective and should be widely implemented. Convincing parents of that fact is proving to be the most difficult obstacle to overcome.

NEWS FEATURE: The vagina catalogues

By Alison McCook

vaginacatalogues.jpgWhen Heather went on vacation last year at the same time that she was participating in an unusual research project, she knew the relatives she was sharing a room with might be curious about what she was sticking inside the hotel freezer. Rather than explaining, “I would say ‘just don’t touch this cup’,” recalls the 34-year-old health counselor from Baltimore. Thankfully, no one did.

Heather (not her real name) was one of 160 healthy, reproductive-age women who took part in a study that asked much more of its participants than the typical research project. The cup in Heather’s minibar freezer contained swabs she had collected from her vagina. Every morning for 10 weeks, she wiped the skin on the inside of her vagina using a sterile applicator with a tuft of fibers at the end, labeled and stored the specimens in the freezer, and answered several personal questions: Had she had sex that day? What kind of sex? Did she use lubricant? Had she worn a thong? Sometimes, sharing these intimate details gave her pause. “I’m thinking, ’who’s going to read this?’,” she says. “There are certain questions they asked that were very personal.”

Researchers assert that knowing such intimate details is essential to really teasing apart the root causes of vaginal disease. By linking lifestyle information with DNA data from the bacteria living in the female genital tract, scientists hope to better understand what drives the daily fluctuations in the bacterial communities living in the vagina—and, thus, what causes disease when the delicately balanced community composition goes out of whack.

(Click here to continue reading.)

Breast isn’t always best

breastpump.jpgYesterday, the New York Times reported that while items like acne creams and denture adhesive are eligible for tax breaks under the new US health care law, breast pumps are not. Breast-feeding boosters like La Leche League are, naturally, up in arms, but the US Internal Revenue Service says that the pumps do not fall under the umbrella of preventative medicine, since breast milk is primarily nutrition.

To counter the IRS, breast-feeding advocates point to research showing that breast-feeding transfers essential antibodies from mother to child. There’s also research suggesting that bacteria in mother’s milk plays a key role in building up a healthy community of intestinal microflora.

But in certain circumstances, breast-feeding can be a vector for harmful microbes as well. In February, the US Centers for Disease Control (CDC) reported the case of a mother in Brazil who, after she received a yellow fever vaccine, passed the virus to her infant through her milk. Hepatitis B virus (HBV) has been detected in the milk of HBV-positive mothers, though it’s unclear if the virus can actually be transmitted through breast-feeding; the most common method of mother-to-child HBV transmission is during delivery itself. If a Hepatitis C-positive mother has cracked or bleeding nipples, she runs a higher risk of transmitting the virus to her infant. UNICEF estimates that if an HIV-positive mother breast-feeds, she’ll pass the virus to her child 5 – 20% of the time.

It’s worth noting that another US government agency, the Transportation Security Administration, classifies breast milk as ‘liquid medication’, which is why mothers are allowed to bring more than three ounces of it on a plane.

Image by planet _oleary via Flickr Creative Commons

I like… my breast cancer activism with substance

pinkribbonThis time of year, the leaves are turning red and yellow and orange, but just about everything else is blushing pink. That’s right: it’s Breast Cancer Awareness Month! The Susan G. Komen for the Cure Foundation has raised more than $1.5 billion for breast cancer research since it started in 1982, and $55 million a year comes from corporate marketing partnerships (including the special edition KFC bucket). We’ve covered these questionable ‘pinkwashing’ practices before. And this October, there’s a new wrinkle to breast cancer activism: half-hearted online awareness campaigns.

The iconic pink ribbon debuted in the early 1990s, and was popularized after the Komen Foundation handed ribbons out to participants in the 1991 Race For the Cure in New York City. Corporations soon discovered that affixing the symbol on their product not only helped their image, but their profit margin as well. In 2006, Campbell’s Soup saw its sales double when it offered pink versions of its iconic cans. In exchange, the company donated $250,000, or a mere 3.5 cents per pink can, to the Susan G. Komen Foundation. When it comes to buying pink products, it’s important to read the fine print: a company may have a cap on the amount of money it’ll donate, and some do not specify what organization the donations are going towards.

Continue reading